Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder, René Gerolami, Gianluca Masi, Paul J Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Masatoshi Kudo, Ann-Lii Cheng, Josep M Llovet, Richard S FinnMarie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han

    Research output: Contribution to journal › Article › peer-review

    2811 Citations (Scopus)
    3042 Downloads (Pure)

    Fingerprint

    Dive into the research topics of 'Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science